Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.